Of interest, NLRP3 inflammasome and, as a result, IL-1β, are also partly modulating the secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9), a well-established therapeutic target in CAD [32]. Here, NLRP3 is linked to coronary artery disorder.